Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;39(5):2236-2255.
doi: 10.1007/s12325-022-02073-w. Epub 2022 Mar 22.

Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan

Andrea Leith  1 , Jeri Kim  2 , Amanda Ribbands  1 , Emily Clayton  1 , Lingfeng Yang  2 , Sameer R Ghate  3
Affiliations

Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan

Andrea Leith et al. Adv Ther. 2022 May.

Abstract

Introduction: Prostate cancer (PC) is the second most common cancer, and the fifth most common cause of cancer-related mortality among male patients, worldwide. In Europe and Japan, the incidence of PC in men in 2020 exceeded that of lung cancer. Although national and regional clinical guidelines for the treatment of metastatic castration-resistant prostate cancer (mCRPC) are available in Europe and Japan, a literature review did not identify a published comparison of differing guidelines, but identified a lack of studies reporting treatment patterns of approved mCRPC treatments in Europe and Japan in normal clinical practice. The objective of this real-world study was to compare national treatment guidelines and real-world treatment for mCRPC in Europe and Japan.

Methods: Physician-reported demographics, clinical characteristics, and treatment data of patients with mCRPC were drawn from the Adelphi Prostate Cancer Disease Specific Programme™, conducted in five European countries and Japan (2020) and analysed descriptively.

Results: All current treatment guidelines recommended the use of novel hormonal agents (NHA-abiraterone/enzalutamide) and chemotherapy (mainly docetaxel), with some intercountry differences, with NHA rechallenge accepted in Germany, Italy and Japan, but not in France, Spain or the United Kingdom. Overall, 271 physicians provided data for 1753 patients. At 1st-line (1L), the most common treatment was NHAs followed by (→) chemotherapy, in all countries. Chemotherapy was the most common 2nd-line (2L) treatment, except in Japan, where 2L NHA use was preferred, and Spain, where both were used equally. NHA → chemotherapy and chemotherapy → NHA were the first and second usual 1L → 2L sequence in most countries, except for France, where the second most common sequence was NHA → NHA, and Japan, with androgen deprivation therapy alone → NHA.

Conclusion: Real-world mCRPC treatment patterns largely reflected national guidelines. It is expected that guidelines and treatment patterns will change with the development of new treatment options.

Keywords: Chemotherapy; Docetaxel; Metastatic castration-resistant prostate cancer; Novel hormonal agents; Treatment guidelines; Treatment patterns.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Timeline for approval of treatments for mCRPC in Europe and Japan
Fig. 2
Fig. 2
Current treatment, NHA and chemotherapy breakout: a at 1L of therapy, b at 2L of therapy, c at 3L+ of therapy, overall and by country
See this image and copyright information in PMC

References

    1. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Thurin NH, et al. Epidemiology of metastatic castration-resistant prostate cancer: a first estimate of incidence and prevalence using the French nationwide healthcare database. Cancer Epidemiol. 2020;69:101833. doi: 10.1016/j.canep.2020.101833. - DOI - PubMed
    1. Morgan C, et al. PCN17 Castration-resistant prostate cancer (CRPC): a UK epidemiology study. Value Health. 2010;13(3):A26. doi: 10.1016/S1098-3015(10)72108-2. - DOI
    1. Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512. doi: 10.1056/NEJMoa040720. - DOI - PubMed
    1. Gravanis I, et al. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2013;18(9):1032–1042. doi: 10.1634/theoncologist.2013-0092. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources